The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma

Tina J Hieken, Travis E. Grotz, Nneka I. Comfere, Jonathan W. Inselman, Elizabeth B Habermann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

T1 melanomas, despite their favorable prognosis, account for 25% of melanoma deaths. The American Joint Committee on Cancer (AJCC) 7th edition melanoma staging, implemented in 2010, replaced the level of invasion with the mitotic rate for T1 substaging, on the basis of prognostic modeling, not prediction of occult lymph nodemetastasis. Previously, sentinel lymph node biopsy (SLNB) was recommended for T1b patients, whereas current guidelines suggest SLNB for select high-risk T1 melanomas. We investigated the effect of this staging change on the performance and outcomes of SLNB for T1 melanoma. Using 2004-2010 data from the Surveillance, Epidemiology, and End Results (SEER) Registry, we identified 32 527 cases of T1 melanoma and compared pre-2010 (N=27 170) with 2010 (N=5357) data. We used χ2- tests, t-tests, and logistic regression models for analysis. After implementation of the 2010 AJCC staging system, SLNB for T1 patients increased from 12.1% (2004) to 14.4% (2010), despite a decrease for T1b melanomas (40.9 to 33.3%; both P values < 0.001), and there was no change in SLNB for melanomas that were 0.7 mm or thicker (38.3 and 39.3%). T-stage, thickness, level, ulceration, age, and geographic region were correlated with SLNB performance (all P values < 0.001). For T1 patients, overall SLN positivity rates were 6.1% pre-2010 and 7.8% in 2010 (P=0.12), while nearly doubling for T1a patients (3.6 to 6.6%, P=0.03). SLN-positive patients had diminished cancer-specific survival (P < 0.001). SLNB for T1b melanomas decreased after AJCC T1 reclassification, without changing for melanomas that were 0.7mm or thicker. SLN positivity rates increased for T1a melanomas, and SLN status was prognostic for T1 patients. Improved strategies to identify high-risk T1 melanoma patients most likely to benefit from SLN surgery and to minimize clinical practice variation would be valuable.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalMelanoma Research
Volume25
Issue number2
DOIs
StatePublished - Mar 15 2015

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Neoplasms
Logistic Models
Neoplasm Staging
Lymph
Registries
Epidemiology

Keywords

  • Cancer outcomes
  • Cancer staging
  • End Results
  • Epidemiology
  • Melanoma
  • Sentinel lymph node biopsy
  • Surveillance
  • T1 melanoma
  • Thin melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. / Hieken, Tina J; Grotz, Travis E.; Comfere, Nneka I.; Inselman, Jonathan W.; Habermann, Elizabeth B.

In: Melanoma Research, Vol. 25, No. 2, 15.03.2015, p. 157-163.

Research output: Contribution to journalArticle

@article{9d71bcee06224c55b684eb25353caa25,
title = "The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma",
abstract = "T1 melanomas, despite their favorable prognosis, account for 25{\%} of melanoma deaths. The American Joint Committee on Cancer (AJCC) 7th edition melanoma staging, implemented in 2010, replaced the level of invasion with the mitotic rate for T1 substaging, on the basis of prognostic modeling, not prediction of occult lymph nodemetastasis. Previously, sentinel lymph node biopsy (SLNB) was recommended for T1b patients, whereas current guidelines suggest SLNB for select high-risk T1 melanomas. We investigated the effect of this staging change on the performance and outcomes of SLNB for T1 melanoma. Using 2004-2010 data from the Surveillance, Epidemiology, and End Results (SEER) Registry, we identified 32 527 cases of T1 melanoma and compared pre-2010 (N=27 170) with 2010 (N=5357) data. We used χ2- tests, t-tests, and logistic regression models for analysis. After implementation of the 2010 AJCC staging system, SLNB for T1 patients increased from 12.1{\%} (2004) to 14.4{\%} (2010), despite a decrease for T1b melanomas (40.9 to 33.3{\%}; both P values < 0.001), and there was no change in SLNB for melanomas that were 0.7 mm or thicker (38.3 and 39.3{\%}). T-stage, thickness, level, ulceration, age, and geographic region were correlated with SLNB performance (all P values < 0.001). For T1 patients, overall SLN positivity rates were 6.1{\%} pre-2010 and 7.8{\%} in 2010 (P=0.12), while nearly doubling for T1a patients (3.6 to 6.6{\%}, P=0.03). SLN-positive patients had diminished cancer-specific survival (P < 0.001). SLNB for T1b melanomas decreased after AJCC T1 reclassification, without changing for melanomas that were 0.7mm or thicker. SLN positivity rates increased for T1a melanomas, and SLN status was prognostic for T1 patients. Improved strategies to identify high-risk T1 melanoma patients most likely to benefit from SLN surgery and to minimize clinical practice variation would be valuable.",
keywords = "Cancer outcomes, Cancer staging, End Results, Epidemiology, Melanoma, Sentinel lymph node biopsy, Surveillance, T1 melanoma, Thin melanoma",
author = "Hieken, {Tina J} and Grotz, {Travis E.} and Comfere, {Nneka I.} and Inselman, {Jonathan W.} and Habermann, {Elizabeth B}",
year = "2015",
month = "3",
day = "15",
doi = "10.1097/CMR.0000000000000143",
language = "English (US)",
volume = "25",
pages = "157--163",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma

AU - Hieken, Tina J

AU - Grotz, Travis E.

AU - Comfere, Nneka I.

AU - Inselman, Jonathan W.

AU - Habermann, Elizabeth B

PY - 2015/3/15

Y1 - 2015/3/15

N2 - T1 melanomas, despite their favorable prognosis, account for 25% of melanoma deaths. The American Joint Committee on Cancer (AJCC) 7th edition melanoma staging, implemented in 2010, replaced the level of invasion with the mitotic rate for T1 substaging, on the basis of prognostic modeling, not prediction of occult lymph nodemetastasis. Previously, sentinel lymph node biopsy (SLNB) was recommended for T1b patients, whereas current guidelines suggest SLNB for select high-risk T1 melanomas. We investigated the effect of this staging change on the performance and outcomes of SLNB for T1 melanoma. Using 2004-2010 data from the Surveillance, Epidemiology, and End Results (SEER) Registry, we identified 32 527 cases of T1 melanoma and compared pre-2010 (N=27 170) with 2010 (N=5357) data. We used χ2- tests, t-tests, and logistic regression models for analysis. After implementation of the 2010 AJCC staging system, SLNB for T1 patients increased from 12.1% (2004) to 14.4% (2010), despite a decrease for T1b melanomas (40.9 to 33.3%; both P values < 0.001), and there was no change in SLNB for melanomas that were 0.7 mm or thicker (38.3 and 39.3%). T-stage, thickness, level, ulceration, age, and geographic region were correlated with SLNB performance (all P values < 0.001). For T1 patients, overall SLN positivity rates were 6.1% pre-2010 and 7.8% in 2010 (P=0.12), while nearly doubling for T1a patients (3.6 to 6.6%, P=0.03). SLN-positive patients had diminished cancer-specific survival (P < 0.001). SLNB for T1b melanomas decreased after AJCC T1 reclassification, without changing for melanomas that were 0.7mm or thicker. SLN positivity rates increased for T1a melanomas, and SLN status was prognostic for T1 patients. Improved strategies to identify high-risk T1 melanoma patients most likely to benefit from SLN surgery and to minimize clinical practice variation would be valuable.

AB - T1 melanomas, despite their favorable prognosis, account for 25% of melanoma deaths. The American Joint Committee on Cancer (AJCC) 7th edition melanoma staging, implemented in 2010, replaced the level of invasion with the mitotic rate for T1 substaging, on the basis of prognostic modeling, not prediction of occult lymph nodemetastasis. Previously, sentinel lymph node biopsy (SLNB) was recommended for T1b patients, whereas current guidelines suggest SLNB for select high-risk T1 melanomas. We investigated the effect of this staging change on the performance and outcomes of SLNB for T1 melanoma. Using 2004-2010 data from the Surveillance, Epidemiology, and End Results (SEER) Registry, we identified 32 527 cases of T1 melanoma and compared pre-2010 (N=27 170) with 2010 (N=5357) data. We used χ2- tests, t-tests, and logistic regression models for analysis. After implementation of the 2010 AJCC staging system, SLNB for T1 patients increased from 12.1% (2004) to 14.4% (2010), despite a decrease for T1b melanomas (40.9 to 33.3%; both P values < 0.001), and there was no change in SLNB for melanomas that were 0.7 mm or thicker (38.3 and 39.3%). T-stage, thickness, level, ulceration, age, and geographic region were correlated with SLNB performance (all P values < 0.001). For T1 patients, overall SLN positivity rates were 6.1% pre-2010 and 7.8% in 2010 (P=0.12), while nearly doubling for T1a patients (3.6 to 6.6%, P=0.03). SLN-positive patients had diminished cancer-specific survival (P < 0.001). SLNB for T1b melanomas decreased after AJCC T1 reclassification, without changing for melanomas that were 0.7mm or thicker. SLN positivity rates increased for T1a melanomas, and SLN status was prognostic for T1 patients. Improved strategies to identify high-risk T1 melanoma patients most likely to benefit from SLN surgery and to minimize clinical practice variation would be valuable.

KW - Cancer outcomes

KW - Cancer staging

KW - End Results

KW - Epidemiology

KW - Melanoma

KW - Sentinel lymph node biopsy

KW - Surveillance

KW - T1 melanoma

KW - Thin melanoma

UR - http://www.scopus.com/inward/record.url?scp=84924985072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924985072&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000143

DO - 10.1097/CMR.0000000000000143

M3 - Article

VL - 25

SP - 157

EP - 163

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 2

ER -